News

In a recent Expert Perspectives video series, Omar Noor, MD, discussed the complexity of chronic hand eczema and how a topical pan-JAK inhibitor can improve quality of life.

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

In an interview with Dermatology Times, Michael O’Donoghue, MD, describes how a standardized protocol supports efficient and consistent delivery of photodynamic therapy.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of February.

Transcriptomic analysis revealed that chronic hand eczema shares overlapping immune signatures with both atopic dermatitis and psoriasis.

BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.

In a 52-week phase 3 study, CT-P43 demonstrated sustained efficacy comparable to reference ustekinumab in adults with moderate to severe plaque psoriasis.

A JAMA Dermatology study found that US veterans with documented Agent Orange exposure had approximately 30% higher odds of developing acral melanoma compared with unexposed veterans.

HS is frequently misdiagnosed for 7 to 10 years because its symptoms resemble conditions like inflamed epidermal cysts, nodulocystic acne, and furuncles.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and patient advocate Suki Tipp discuss the clinical, emotional, and financial toll of delayed diagnosis of indolent systemic mastocytosis.

In case you missed it, this week we had news on phase 3 remibrutinib data for CIndU subtypes, psoriasis “super responders” on risankizumab, the approval of difamilast ointment, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.

Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.

Castle Biosciences’ AdvanceAD-Tx test stratifies patients by molecular profile, identifying patients more likely to achieve faster and deeper responses with JAKs compared with Th2-targeted treatments.

At IMCAS, Anne-Cécile Chevrier revealed new Galderma data on menopause and skin, urging earlier education and proactive treatment choices.

In a conversation with Dermatology Times, Del Rosso highlighted the growing range of systemic and procedural therapies available to clinicians.

Michael O’Donoghue, MD, outlines how delegating PDT workflows to trained medical assistants can preserve physician time while maintaining treatment quality.

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

A post hoc analysis found that abrocitinib provided faster itch relief than dupilumab in adults with itch-dominant atopic dermatitis.

In pivotal studies, significantly more patients achieved clear or almost clear skin after 4 weeks of twice-daily difamilast compared with vehicle.

Even without deep penetration, peptide moisturizers can improve the skin’s appearance through hydration and smoothing effects.

Catch up on coverage from the 24th annual South Beach Symposium.

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

Novartis reports RemIND phase 3 success and submits a supplemental New Drug Application to the FDA for symptomatic dermographism.

In the phase 3b TOGETHER-PsO trial, ixekizumab plus tirzepatide led to significantly higher rates of complete skin clearance and ≥10% weight loss.

This review of the latest dermatological studies includes insights on racial differences in PCOS-related teenage acne, CVD in patients with HS and lymphedema, propranolol for infantile hemangioma, and more.